Vir Biotechnology Stock News

An expert panel at the World Health Organization ((WHO)) recommended the use of two treatments developed by Eli Lilly (LLY) and GlaxoSmithKline (GSK)/Vir Biotechnology (VIR) for

Glaxo (GSK) and Vir are looking to get authorization for the intramuscular administration of their COVID-19 drug candidate, sotrovimab, which is currently authorized for intravenous administration.

Don't wait too long to buy shares of these two companies.

Vir Biotechnology <> expanded its partnership with the Bill & Melinda Gates Foundation to advance technologies for developing broadly neutralizing antibodies designed to provide

GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announced the submission to the FDA of an application seeking an amendment to the Emergency Use Authorization ((EUA)) for sotrovimab…

Vir Biotechnology, Inc. (NASDAQ: VIR ) today announced an expansion of its partnership with the Bill & Melinda Gates Foundation to include the advancement of innovative platform technologies in the development of broadly neutralizing antibodies designed to provide a "vaccinal effect" for the treatment of HIV and prevention of malaria. This novel program combines Vir''s extensive immunologic and virologic expertise with the Gates Foundation''s long-standing global health leadership to address two of the world''s most challenging infectious diseases. "Vir''s partnership with the Bill & Melinda Gates Foundation has been a formative and essential part of our company history beginning with our T-cell vaccine program targeting HIV and tuberculosis. This expanded collaboration into a second platform technology supports our shared goal of developing innovative solutions for prevention and treatment of global infectious diseases. We look forward to applying the Full story available on Benzinga.

IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda

Shares of Vir Biotechnology Inc. VIR, -1.60% were up 1.0% in trading on Thursday after the company and GlaxoSmithKline GSK, -0.01% formally asked the Food and Drug Administration to update the authori

Vir Biotechnology, Inc. (VIR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the nea

Vir Biotechnology <> has surged more than a tenth in value, adding to its modest gain on Tuesday that followed its announcement over a fresh U.S

The U.S. government enters into an agreement with Glaxo (GSK) and Vir Biotechnology (VIR) to procure an additional 600,000 doses of sotrovimab for early treatment of COVID-19.

After losing some value lately, a hammer chart pattern has been formed for Vir Biotechnology, Inc. (VIR), indicating that the stock has found support. This, combined with an upward trend in earnings e

The U.S. has agreed to buy 600,000 more doses of GlaxoSmithKline plc (NYSE: GSK ) and Vir Biotechnology Inc''s (NASDAQ: VIR ) COVID-19 antibody therapy for an undisclosed sum. The companies would supply the additional doses of sotrovimab to the U.S. in Q1 of 2022, taking the Full story available on Benzinga.com

By Pushkala Aripaka (Reuters) The United States has agreed to buy 600,000 more doses of GSK and Vir Biotechnologys COVID-19 antibody therapy for an undisclosed sum, as the country bolsters its arsenal of treatments against the Omicron coronavirus variant.